Last reviewed · How we verify
NCT04132934: DIA-RAMADAN
Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN
trial in Type 2 Diabetes in 1,200 participants. Completed in 4 October 2019.
4 October 2019
Quick facts
| Lead sponsor | Servier Affaires Médicales |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,200 |
| Start date | 11 March 2019 |
| Primary completion | 4 October 2019 |
| Estimated completion | 4 October 2019 |
| Sites | 1 location across France |
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Servier Affaires Médicales — full company profile →
Who can join
18 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this observational study is to assess effectiveness and tolerability of gliclazide MR 60mg during RAMADAN in a real world setting in 9 countries from Asia Pacific and Middle East/North Africa
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN.
Hassanein M, Al Sifri S, Shaikh S, Abbas Raza S, et al · · 2020 · cited 26× · PMID 32330510 · DOI 10.1016/j.diabres.2020.108154 -
56<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : 21-25 September 2020.
· 2020 · cited 9× · PMID 32840677 · DOI 10.1007/s00125-020-05221-5 -
Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN.
Hassanein M, Al Sifri S, Shaikh S, Raza SA, et al · · 2021 · cited 2× · PMID 33974216 · DOI 10.1007/s13300-021-01067-1 -
Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study.
Uddin MF, Khan MA, Selim S, Sultana N, et al · · 2024 · cited 1× · PMID 38294337 · DOI 10.57264/cer-2023-0132
Verify or expand the search:
- PubMed search for NCT04132934
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Servier Affaires Médicales trials
Trials by the same sponsor.
- NCT06155136 — RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan · active not recruiting
- NCT06298045 — Effectiveness of a Combination of Trimetazidine With One Hemodynamic Agent in Patients Recently Diagnosed With Stable An · unknown
- NCT05907057 — An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m · Phase 3 · recruiting
- NCT05876754 — An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma · Phase 3 · recruiting
- NCT06704815 — Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Peri · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04132934 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Servier Affaires Médicales
- Last refreshed: 5 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04132934.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing